Artiva Biotherapeutics (NASDAQ:ARTV) Stock Rating Raised to Sell at Wall Street Zen

Artiva Biotherapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen upgraded Artiva Biotherapeutics from “strong sell” to “sell,” while analysts overall have a consensus “hold” rating and an average price target of $24.80.
  • Shares opened at $3.79, well below their 50-day average of $5.97; the company reported a quarterly loss of $0.56 per share, slightly missing the $0.55 consensus estimate.
  • Company insiders sold a combined 136,619 shares over the past 90 days, worth about $1.08 million; CEO Fred Aslan and insider Christopher Horan were among the sellers.
  • MarketBeat previews the top five stocks to own by December 1st.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) was upgraded by Wall Street Zen from a "strong sell" rating to a "sell" rating in a report released on Sunday, Wall Street Zen reports.

Other analysts have also issued reports about the company. Needham & Company LLC lowered Artiva Biotherapeutics from a "buy" rating to a "hold" rating in a report on Tuesday, October 27th. Wedbush downgraded Artiva Biotherapeutics from an "outperform" rating to a "neutral" rating and set a $4.00 price objective on the stock. in a research note on Tuesday, October 27th. Cantor Fitzgerald reissued an "overweight" rating and issued a $40.00 price objective on shares of Artiva Biotherapeutics in a report on Friday, October 2nd. Jefferies Financial Group cut Artiva Biotherapeutics from a "buy" rating to a "hold" rating and set a $4.00 price target for the company. in a research report on Thursday, October 29th. Finally, TD Cowen lowered Artiva Biotherapeutics from a "buy" rating to a "hold" rating in a research note on Tuesday, October 27th. Two analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $24.80.

View Our Latest Stock Report on Artiva Biotherapeutics

Artiva Biotherapeutics Stock Down 1.2%

ARTV stock opened at $3.79 on Friday. The company's 50-day moving average price is $5.97 and its two-hundred day moving average price is $7.93. Artiva Biotherapeutics has a 12 month low of $2.96 and a 12 month high of $14.53. The firm has a market cap of $187.09 million, a P/E ratio of -1.27 and a beta of 2.67.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.56) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.01). Equities analysts predict that Artiva Biotherapeutics will post -2.74 EPS for the current year.

Insider Buying and Selling

In other news, CEO Fred Aslan sold 23,463 shares of the company's stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $7.20, for a total transaction of $168,933.60. Following the transaction, the chief executive officer owned 1,519,606 shares of the company's stock, valued at approximately $10,941,163.20. This represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Christopher Horan sold 10,340 shares of the stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $6.84, for a total value of $70,725.60. Following the completion of the sale, the insider owned 312,744 shares in the company, valued at approximately $2,139,168.96. The trade was a 3.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 136,619 shares of company stock worth $1,081,019. 1.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. RA Capital Management L.P. boosted its stake in Artiva Biotherapeutics by 3.0% in the third quarter. RA Capital Management L.P. now owns 18,489,293 shares of the company's stock valued at $131,644,000 after acquiring an additional 533,651 shares in the last quarter. 5AM Venture Management LLC acquired a new stake in shares of Artiva Biotherapeutics in the second quarter valued at about $22,827,049. Blue Owl Capital Holdings LP acquired a new position in Artiva Biotherapeutics in the 2nd quarter valued at $8,483,000. BlackRock Inc. acquired a new position in Artiva Biotherapeutics in the 2nd quarter valued at about $6,739,000. Finally, State Street Corp grew its position in Artiva Biotherapeutics by 2.5% in the 3rd quarter. State Street Corp now owns 339,761 shares of the company's stock valued at $2,419,000 after acquiring an additional 8,233 shares in the last quarter.

Artiva Biotherapeutics Company Profile

(Get Free Report)

Artiva Biotherapeutics is a San Diego-based clinical-stage biotechnology company developing allogeneic, or donor-derived, natural killer (NK) cell therapies. Its approach is designed to provide ready-made cell treatments for patients with cancer and autoimmune diseases. The company's lead candidate, AlloNK (also known as AB-101), is an investigational NK cell therapy being studied in combination with antibody treatments. Artiva is evaluating its potential in autoimmune conditions and in cancers, including B-cell malignancies.

Recommended Stories

Analyst Recommendations for Artiva Biotherapeutics (NASDAQ:ARTV)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Artiva Biotherapeutics Right Now?

Before you consider Artiva Biotherapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Artiva Biotherapeutics wasn't on the list.

While Artiva Biotherapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines